It took ninety years. That is how long doctors spend calling it the wrong thing.
Polycystic ovary syndrome, which affects roughly one in eight women worldwide, was named in 1935 by physicians who peered at ovaries during surgery and noticed they looked lumpy. They called what they saw cysts. They were not cysts.
They were arrested follicles, eggs that had failed to mature, and the distinction matters enormously, because the word polycystic sent generations of clinicians, researchers and patients chasing the wrong organ for the wrong problem. The condition is now being renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a process announced in the Lancet on May 12 and presented the same day at the European Congress of Endocrinology in Prague.
The renaming was led by Prof Helena Teede, an endocrinologist and director of the Monash Centre for Health Research and Implementation in Melbourne. Fourteen years of collaboration. Fifty-six medical and patient organisations. Surveys of thousands of clinicians and patients across six continents.
By any measure, it is an extraordinary amount of effort to correct a mistake that most specialists have known about since at least 1995, when academic articles first started raising it formally, and which the US National Institutes of Health flagged as a problem in 2012. Nothing happened for another decade. This is how medical nomenclature works.
The practical consequences of the old name were not trivial. Up to 70 per cent of people with the condition remain undiagnosed. Because PCOS was framed as primarily gynaecological, research funding and clinical training concentrated on reproductive outcomes, while the metabolic dimensions, including insulin resistance, cardiovascular risk and weight dysregulation, were treated as secondary concerns.
Women reported being told they did not look right for the diagnosis, that treatment was only relevant if they wanted children, that they should simply avoid putting on weight, as if the condition were a failure of personal discipline rather than a hormonal disorder affecting multiple systems simultaneously.
Maddy Mavrikis, 28, was diagnosed at fifteen and told she would probably never have children. She did not have polycystic ovaries. Her GP told her she would develop them eventually. The insulin resistance, the androgens, the acne: all of it folded into a name that pointed at the wrong place.
The word reproductive was considered and rejected for the new name. In many parts of the world, Teede noted at the Prague conference, labelling a woman with a reproductive condition carries direct implications for her social worth.
The organisers were alive to this. That they spent serious time on it is, at minimum, an improvement on the original naming process, which involved no patients at all and got it wrong for nine decades. The new name will be fully effective in 2028, when international clinical guidelines are next updated. Progress, by any measure, arrives slowly.
